NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 11:02AM ET
0.6798
Dollar change
-0.0132
Percentage change
-1.90
%
Index- P/E- EPS (ttm)-0.84 Insider Own68.53% Shs Outstand51.78M Perf Week0.04%
Market Cap35.21M Forward P/E- EPS next Y-0.80 Insider Trans0.28% Shs Float16.30M Perf Month0.58%
Enterprise Value-46.00M PEG- EPS next Q-0.10 Inst Own16.12% Short Float16.10% Perf Quarter-7.03%
Income-54.30M P/S3.80 EPS this Y44.05% Inst Trans-27.43% Short Ratio2.04 Perf Half Y-29.92%
Sales9.27M P/B3.29 EPS next Y-31.76% ROA-58.29% Short Interest2.62M Perf YTD-28.82%
Book/sh0.21 P/C0.40 EPS next 5Y-4.53% ROE-297.84% 52W High1.70 -60.01% Perf Year-26.42%
Cash/sh1.72 P/FCF1.67 EPS past 3/5Y26.76% -11.55% ROIC-313.20% 52W Low0.62 9.65% Perf 3Y-72.81%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin80.74% Volatility4.04% 4.98% Perf 5Y-
Dividend TTM- EV/Sales-4.96 EPS Y/Y TTM67.24% Oper. Margin-614.16% ATR (14)0.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.96 Sales Y/Y TTM- Profit Margin-585.54% RSI (14)44.90 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio1.96 EPS Q/Q71.18% SMA20-0.26% Beta-0.12 Target Price4.00
Payout- Debt/Eq0.73 Sales Q/Q- SMA50-10.81% Rel Volume0.14 Prev Close0.69
Employees64 LT Debt/Eq0.62 EarningsMay 08 BMO SMA200-21.91% Avg Volume1.29M Price0.68
IPOOct 22, 2021 Option/ShortNo / Yes EPS/Sales Surpr.6.59% -34.09% Trades Volume50,956 Change-1.90%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jul-02-25 04:30PM
Jun-10-25 04:30PM
Jun-05-25 06:38PM
Jun-03-25 04:30PM
Jun-02-25 08:46AM
06:11AM Loading…
06:11AM
May-31-25 08:00AM
May-08-25 07:30AM
May-02-25 04:30PM
Apr-23-25 04:30PM
Apr-04-25 04:30PM
Mar-11-25 08:45AM
07:30AM
Feb-24-25 04:30PM
Feb-13-25 04:17AM
10:44AM Loading…
Feb-12-25 10:44AM
07:35AM
07:33AM
Feb-03-25 04:30PM
Jan-22-25 09:00AM
Jan-21-25 05:05PM
Jan-17-25 04:30PM
Jan-10-25 05:00PM
Dec-19-24 07:30AM
Dec-16-24 07:30AM
Dec-09-24 09:55AM
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
Oct-30-24 09:01AM
09:05AM Loading…
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shannon James SamuelDirectorJun 16 '25Buy0.6945,00030,87045,000Jun 18 04:57 PM
Shannon James SamuelDirectorJun 17 '25Buy0.6925,00017,21570,000Jun 18 04:57 PM
Russo RenePRESIDENT AND CEOJun 16 '25Buy0.6836,28924,680281,172Jun 18 04:56 PM
Frankenfield Christopher JamesChief Financial OfficerJan 02 '25Sale0.986,9546,84112,421Jan 03 04:15 PM
Brennan Kevin M.SVP, FINANCE AND ACCOUNTINGJan 02 '25Sale0.981,8031,7743,197Jan 03 04:15 PM
GILEAD SCIENCES, INC.10% OwnerDec 18 '24Buy1.041,759,9781,830,3779,105,451Dec 19 04:19 PM